EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Therapeutic targeting of neuroinflammation in sphingolipidosis

Ebru Ada, Volkan Seyrantepe

Molecular Immunology · 2025

DOI: 10.1016/j.molimm.2025.09.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Immunology, 2025. Verfasst von Ebru Ada und 1 weiteren Autor:innen. Beteiligte Einrichtung: Izmir Institute of Technology, Department of Molecular Biology and Genetics, Gulbahce Campus, Urla, İzmir 35430, Turkey. Hauptthemen laut MEDLINE: Sphingolipidoses, Neuroinflammatory Diseases. Die Arbeit nennt 188 Literaturangaben. Gefördert von: European Cooperation in Science and Technology, Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lysosomal storage diseases (LSDs) are a class of hereditary metabolic disorders primarily caused by lysosomal enzyme defects, leading to the accumulation of undegraded substrates. Sphingolipidoses, a subset of LSDs, are primarily associated with profound involvement of the central nervous system (CNS), characterized by progressive neurodegeneration due to massive sphingolipid accumulation. A common pathological feature among many CNS-involved LSDs is the early activation of microglia and astrocytes, which often precedes and predicts regions of subsequent neuronal loss. The extent to which neuroinflammation disrupts CNS homeostasis appears to be determined by its onset, magnitude, and duration. Although neuroinflammatory processes are increasingly recognized as critical contributors to disease progression in sphingolipidoses, the molecular mechanisms underlying glial activation and the initiation of inflammatory cascades remain incompletely understood. Therefore, mouse models of sphingolipidoses have been instrumental in elucidating these pathogenic processes and provide valuable platforms for evaluating therapeutic strategies. This review critically examines the role of neuroinflammation in sphingolipidoses, summarizes insights derived from pre-clinical models, and discusses the therapeutic potential of anti-inflammatory interventions to mitigate CNS pathology and improve clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SphingolipidosesNeuroinflammatory DiseasesHumansAnimalsMiceNeurogliaCentral Nervous SystemDisease Models, Animal

Stichwörter der Autor:innen

NeuroinflammationSphingolipidosisTherapy

Autor:innen und Institutionen

  • Izmir Institute of Technology, Department of Molecular Biology and Genetics, Gulbahce Campus, Urla, İzmir 35430, Turkey.
  • Izmir Institute of Technology, Department of Molecular Biology and Genetics, Gulbahce Campus, Urla, İzmir 35430, Turkey; İzmir Institute of Technology, IYTEDEHAM, Gulbahce Campus, Urla, İzmir 35430, Turkey. Electronic a…

Förderung

  • European Cooperation in Science and Technology
  • Türkiye Bilimsel ve Teknolojik Araştırma Kurumu

Zitieren

APA

Ada, E., & Seyrantepe, V. (2025). Therapeutic targeting of neuroinflammation in sphingolipidosis. Molecular Immunology. https://doi.org/10.1016/j.molimm.2025.09.005

Vancouver

Ada E, Seyrantepe V. Therapeutic targeting of neuroinflammation in sphingolipidosis. Molecular Immunology. 2025. doi:10.1016/j.molimm.2025.09.005

BibTeX
@article{Ada2025,
  author = {Ada, Ebru and Seyrantepe, Volkan},
  title = {Therapeutic targeting of neuroinflammation in sphingolipidosis},
  journal = {Molecular Immunology},
  year = {2025},
  doi = {10.1016/j.molimm.2025.09.005}
}
Kostenlos starten →